Mustang Bio, Inc.

MBIO

US62818Q2030

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
0.2012 ^USD	-4.82%		-4.14%	-85.10%

15/05	Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02/05	Mustang Bio, Inc. announced that it has received $3.3 million in funding	CI

Mustang Bio, Inc. Announces Resignation of David Horin as Interim Chief Financial Officer

November 14, 2017 at 07:24 pm IST

Mustang Bio, Inc. announced that on November 14, 2017 David Horin resigned as Interim Chief Financial Officer of the company.

Latest news about Mustang Bio, Inc.

Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Mustang Bio, Inc. announced that it has received $3.3 million in funding	02/05	CI
Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants	30/04	MT
Mustang Bio, Inc. announced that it expects to receive $3.3 million in funding	29/04	CI
North American Morning Briefing : Stock Futures Rise Despite Middle East Tensions	15/04	DJ
Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	28/03	CI
Mustang Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03	CI
Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma	07/03	CI
Mustang Bio, Inc Appoints James Murphy as Interim Chief Financial Officer	26/01	CI
Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer	12/12	CI
Mustang Bio, Inc. Announces Executive Changes	12/12	CI
Mustang Bio, Inc. Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology Annual Meeting	11/12	CI
Mustang Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Mustang Bio, Inc. announced that it has received $4.742942 million in funding	03/11	CI
Mustang Bio, Inc. Announces Interim Phase 1/2 Data from Mustang's Multicenter Clinical Trial of MB-106	03/11	CI
Mustang Bio Shares Down 12% After Direct Offering Prices	26/23/26	DJ
Mustang Bio to Start Cancer Trial Following FDA Acceptance of IND Application for MB-109; Shares Jump	26/23/26	MT
Mustang Bio Shares Rise 13% After FDA Acceptance of IND Application	26/23/26	DJ
Mustang Bio Gets FDA Acceptance of IND Application for MB-109 Cancer Treatment	26/23/26	DJ
Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-109, A Novel Combination of MB-101 (IL13RA2-Targeted Car-T Cell Therapy) and MB-108 (HSV-1 Oncolytic Virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma	26/23/26	CI
Mustang Bio, Inc. announced that it expects to receive $4.742942 million in funding	26/23/26	CI
Mustang Bio Says Cancer Treatment MB-106 Shows Clinical Response, Committee Approves Increased Dosage	16/23/16	MT
Mustang Bio, Inc. Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy	16/23/16	CI
BTIG Adjusts Price Target on Mustang Bio to $16 From $20, Maintains Buy Rating	15/23/15	MT
Mustang Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. It is developing a CAR T therapy for hematologic malignancies in partnership with Fred Hutch targeting CD20 (MB-106). In partnership with St. Jude, its X-linked Severe Combined Immunodeficiency (XSCID) gene therapy programs (MB-117 and MB-217) are being developed under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.2012 USD

Average target price

6 USD

Spread / Average Target

+2,882.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MUSTANG BIO, INC.	-85.10%	25.05L
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	12TCr
REGENERON PHARMACEUTICALS, INC.	+11.60%	11TCr
BIONTECH SE	-4.68%	2.43TCr
ARGENX SE	-0.82%	2.2TCr
GENMAB A/S	-10.12%	1.82TCr
WUXI APPTEC CO., LTD.	-42.12%	1.64TCr
BEIGENE, LTD.	-17.47%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+2.77%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+34.58%	1.23TCr

Bio Therapeutic Drugs

Mustang Bio, Inc.

Equities

MBIO

US62818Q2030

Biotechnology & Medical Research

Mustang Bio, Inc. Announces Resignation of David Horin as Interim Chief Financial Officer

Latest news about Mustang Bio, Inc.

Chart Mustang Bio, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs